Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Carcinoma, Islet Cell 1Carcinoma 1Carcinoid Tumor 1

Interventions

Everolimus 3tislelizumab 1surufatinib 1romidepsin 1regorafenib 1pembrolizumab 1pasireotide 1lutetium Lu 177 dotatate 1folfirinox 1fludarabine phosphate 1epothilone B 1cixutumumab 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Radiosurgery 1Octreotide 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Lactones 1LY2584702 1Interleukin-13 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Erlotinib Hydrochloride 1Embolization, Therapeutic 1Doxorubicin 1Depsipeptides 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × cixutumumab × NET × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡